



Bioactive Lysophosphatidylcholine 16:0 and 18:0 Are Elevated in Lungs of Asthmatic Subjects

Mark Yoder,¹ Yan Zhuge,² Yang Yuan,⁴ Oksana Holian,² Sherry Kuo,¹ Richard van Breemen,⁴ Larry L. Thomas,³ Hazel Lum^{2*}

¹Department of Medicine, Rush University Medical Center, Chicago, IL, USA

²Department of Pharmacology, Rush University Medical Center, Chicago, IL, USA

³Department of Immunology and Microbiology, Rush University Medical Center, Chicago, IL, USA

⁴Department of Medicinal Chemistry & Pharmacognosy, University of Illinois, Chicago, IL, USA

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/3.0/>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Purpose: Asthma is a chronic inflammatory disease of the airways, and is associated with upregulation of phospholipase A₂ (PLA₂), the enzyme that hydrolyzes phosphatidylcholine, producing lysophosphatidylcholine (LPC) and free fatty acids. LPC is a lipid mediator with known pro-inflammatory and pro-atherogenic properties, and is believed to be a critical factor in cardiovascular diseases. We postulate that asthmatic subjects have an elevated content of LPC in the lung lining fluids. **Methods:** Eight non-asthmatic controls and seven asthmatic subjects were recruited for broncho-alveolar lavage fluids (BALF) collection for analysis of LPC by high performance liquid chromatography-tandem mass spectrometry. **Results:** LPC16:0 and LPC18:0 were significantly elevated in the BALF of asthmatics with impaired lung function characteristic of moderate asthma, but not mild asthma. The increased LPC content in BALF was accompanied by increased PLA₂ activity. Furthermore, qRT-PCR analysis of the BALF cell fraction indicated increased secretory PLA₂-X (sPLA₂-X). **Conclusions:** The increased LPC content in the lung lining fluids is a potential critical lipid mediator in the initiation and/or progression of airway epithelial injury in asthma.

Key Words: Lysophosphatidylcholine; asthma; phospholipase A₂

INTRODUCTION

Lysophosphatidylcholine (LPC) is a lipid mediator with pro-inflammatory and pro-atherogenic activities. It is believed to be a critical factor underlying cardiovascular diseases,^{1,2} and several pathological conditions are associated with elevated LPC levels in the circulation.³⁻⁵ LPC has a broad-spectrum of pro-inflammatory activities, including promotion of cell growth,⁶ migration,^{7,8} secretion of chemokines and cytokines,^{9,10} generation of reactive oxygen species,¹¹ and upregulation of adhesion molecules such as ICAM-1, VCAM-1, and selectins.¹²

Evidence implicates involvement of LPC in inflammatory injury of lungs, such as acute lung injury and chronic diseases such as asthma. In lungs from late stage adult respiratory distress syndrome,¹³ lungs challenged with antigen¹⁴ or instilled with lipopolysaccharide,¹⁵ elevated amounts of LPC are reported in the broncho-alveolar lavage fluids (BALF). Furthermore, the administration of exogenous LPC into lungs of animal models promotes eosinophil infiltration,¹⁶ increases airway resistance,^{16,17} and increases airway epithelial permeability.^{18,19} These findings suggest that elevated levels of LPC in the extracellular lung flu-

ids can induce inflammatory injury on the airway and alveolar cell populations. To date, the role of LPC in lung diseases is incomplete.

Asthma is a chronic inflammatory disease of the airways characterized by epithelial injury, leukocytic infiltration, airway hyper-reactivity, and airway wall remodeling. We postulate that the chronic inflammation is attributed, at least in part, to elevated amounts of LPC in the lungs. In lungs of asthmatic subjects^{14,20-22} and in animal models of asthma,^{23,24} the LPC-generating enzyme, phospholipase A₂ (PLA₂) is significantly increased. PLA₂ hydrolyzes membrane phosphatidylcholines and oxidized phosphatidylcholines at the *sn*-2 position, generating LPC following release of the free fatty acid.²⁵ However, it is not known whether the inherent LPC content in lungs is increased in asth-

Correspondence to: Hazel Lum, PhD, Department of Pharmacology, Rush University Medical Center, 1735 W. Harrison St., Cohn Research Building, Suite 406, Chicago, IL 60612, USA.

Tel: +1-312-563-2560; Fax: +1-312-563-3552; E-mail: hlum@rush.edu

Received: January 4, 2013; Accepted: February 13, 2013

• There are no financial or other issues that might lead to conflict of interest.

matics. To begin to investigate the involvement of LPC in asthma, this study determined LPC levels in the BALF from asthmatic subjects.

MATERIALS AND METHODS

BALF collection and preparation

Eight non-asthmatic controls and seven asthmatic subjects were recruited for bronchoscopy and BALF collection under an approved protocol by Institutional Review Board. The asthmatics were further grouped as mild or moderate based on spirometric measures of forced expiratory volume in 1 second (FEV1) and/or clinical features (Table 1). The BALF was filtered to remove mucus and visible cellular debris, and an aliquot used for cell count determination. The remaining BALF was centrifuged in which the supernatant was stored at -80°C for later analysis of LPC content, protein concentration, and PLA₂ activity; whereas the cell pellet for qRT-PCR of PLA₂.

Quantification of LPC species

The supernatant fraction of the BALF was extracted for quantification of the 3 most common and biologically-active LPC species (LPC16:0, LPC18:0, and LPC18:1) by high performance liquid chromatography-tandem mass spectrometry (LC-MS-MS). The samples were spiked with LPC19:0 (140 ng/mL) as an internal standard. The system consisted of a Thermo TSQ Quantum triple quadrupole mass spectrometer (San Jose, CA) equipped with a Waters 2695 HPLC system (Milford, MA) and a Waters XTerra C₁₈ column, and has a detection limit for LPC of 10 pg. The limit of detection of LPC was 10 pg and the limit of quantitation was 25 pg. The standard curves for the LPCs over the concentration range of 2.5-500 ng/mL were linear with a coefficient of determination (R^2) >0.995 .

Microplate assays

PLA₂ activity was measured from the supernatant fraction of BALF using a fluorescent phosphatidylcholine substrate analog (Red/Green BODIPY PC-A₂). Cleavage of the substrate analog by PLA₂ results in increased fluorescence detected at 515 nm. The chemokine, IL-8, was measured as a prototypic inflammatory marker in the BALF using an enzyme-linked immunosorbent assay (ELISA) kit (BioLegend). Absorbance was read at 450 nm.

Quantification of PLA₂ mRNA

The cell fraction of the BALF was evaluated by qRT-PCR as a potential source of secreted PLA₂. Total RNA was isolated using Trizol according to manufacturer's instructions, quantified by absorbance at 260 nm (NanoDrop DNA/RNA/protein spectrophotometer), and cDNA synthesized using the high capacity cDNA Archive Kit (Applied Biosystems, Foster City, CA). The cDNA was amplified with SYBR[®] Green PCR master mix kit

(Applied Biosystems) using the BIORAD MyiQ single color real-time PCR detection system (Hercules, CA) in a 96-well format. Primers were designed to recognize major types of human PLA₂ and the internal control gene, glyceraldehyde-3-phosphate dehydrogenase as follows: sPLA₂-IIa (NM_000300), sPLA₂-V (NM_000929), sPLA₂-X (NM_003561), sPLA₂-XII (NM_030821), cPLA₂-IVa (NM_024420), iPLA₂-VI (NM_003560), GAPDH (NM_002046).

Statistics

Single sample data were analyzed by the 2-tailed, independent Student's *t*-test (SPSS 15.0, Excel).

RESULTS

Table 1 summarizes the subjects' clinical characteristics, of which the lung function data (FEV1) were used to categorize subjects into non-asthmatic control, mild- or moderate-asthmatics according to guidelines from the Global Initiative for Asthma.²⁶ As expected, the BALF in the mild- and moderate-asthmatics presented with several indices of inflammation (Table 1). A cell differential analysis of BALF from mild-asthmatics indicated higher percentages of eosinophils and lymphocytes relative to non-asthmatic controls. These proportions of leuko-

Table 1. Study subject profile

| | Non-asthmatic | Mild-asthmatic | Moderate-asthmatic |
|---|----------------|----------------|--------------------|
| Clinical characteristics* | | | |
| FEV1/FVC (%) | 80.0±8.3 | 74.7±7.0 | 67.5±11.2 |
| FEV1 (% predicted) | 95.9±14.5 | 88.7±10.4 | 75.8±11.8 |
| SABA use (n) | 0 | 2 | 4 |
| LABA use (n) | 0 | 0 | 4 |
| Inhaled steroid use (n) | 0 | 0 | 4 |
| LTRA (n) | 0 | 0 | 2 |
| Age (years) | 28.5±8.8 | 33.3±5.1 | 33.5±17.0 |
| N | 8 | 3 | 4 |
| Inflammatory indices in BALF [†] | | | |
| Cell differential: | | | |
| % Eosinophil | 1.10±0.57 | 11.44±8.81 | 19.28±15.10 |
| % Neutrophil | 5.10±2.34 | 3.84±0.77 | 19.66±16.36 |
| % Lymphocyte | 11.40±3.55 | 18.32±2.54 | 24.22±0.46 |
| % Macrophage | 69.69±6.33 | 56.14±7.68 | 34.42±15.99 |
| Total cell counts (mL) | 122,188±22,908 | 156,667±46,668 | 175,000±58,657 |
| Total protein (mg/mL) | 0.24±0.04 | 0.27±0.01 | 0.33±0.07 |
| IL-8, Absorbance units | 0.13±0.01 | 0.17±0.03 | 0.28±0.10 |
| BALF recovered (mL) | 41.6±7.1 | 30.0±13.2 | 32.8±5.4 |

FEV1, forced expiratory volume in 1 second; FVC, forced expiratory volume; SABA, short-acting bronchodilator agent; LABA, long-acting bronchodilator agent; LTRA, leukotriene receptor antagonist.

*Results reported as average±SD. [†]Results reported as average±SE.

cytes further increased in the moderate-asthmatics, which now included neutrophils. An upward trend was observed in the total cell count and protein content in the BALF of mild- and moderate-asthmatics. We also found a progressive increase of IL-8 content in the non-asthmatics to the mild- and moderate-asthmatics. In summary, the BALF of asthmatics contain several markers of inflammation that progress with degree of asthma severity.

We found that non-asthmatics have basal levels of all 3 LPC species at a range of 180-250 ng/mL of BALF (Fig. 1). The saturated species LPC16:0 and LPC18:0 were significantly increased in asthmatic subjects with FEV1 characteristic of moderate asthmatics (Table 1) when compared with the non-asthmatic controls (Fig. 1). Asthmatic subjects with less severe FEV1 representing the mild-asthmatics showed no increases of the LPC species relative to controls. The findings indicate that the lung mucosal surface of moderate-asthmatics is likely to be chroni-

cally exposed to ~1.3 to 1.9-fold higher amounts of LPC16:0 and LPC18:0, respectively, than in non-asthmatics.

We next determined whether the increased LPC content in lungs of moderate-asthmatics could be attributed to secreted PLA₂, hydrolyzing phosphatidylcholines of cell membranes or surfactant. Measures of the PLA₂ activity of BALF indicated that moderate-asthmatics, but not mild-asthmatics, show a 3-fold increase over non-asthmatics (Fig. 2A). The infiltrated lung leukocytes as well as the airway epithelium are the likely cell populations that secrete PLA₂ into the lung luminal fluids. Quantitative RT-PCR evaluation of the cell fraction of the BALF indicated that subtype secretory sPLA₂-X mRNA was upregulated in moderate-asthmatics, but there were no changes in other subtypes (sPLA₂-XII, cPLA₂-IVa and iPLA₂-VI) (Fig. 2B). These findings suggest that sPLA₂-X is likely a key subtype in the generation of LPC in asthmatic subjects.




Fig. 1. LPC content in BALF. (A) Representative LC-MS-MS chromatograph for LPC16:0, LPC18:0, and LPC18:1 in BALF samples from non-asthmatic and asthmatic subjects; dashed line = non-asthmatic subjects; solid line = moderate-asthmatic subjects; LPC19:0 is internal standard. (B) LPC16:0, LPC18:0, and LPC18:1 reported as average ng/mL \pm SE; non-asthmatics (n=8), mild-asthmatics (n=3), moderate-asthmatics (n=3). * P <0.05. ** P =0.01.




Fig. 2. PLA₂ content in BALF. (A) PLA₂ activity of the cell-free fraction of BALF was measured using a fluorescent phosphatidylcholine analog in a microplate assay format. Activity reported as average relative fluorescent units (RFU) \pm SE. (B) PLA₂ mRNA of the cell pellet fraction of BALF was determined by quantitative RT-PCR using primer pairs for human sPLA₂-X, sPLA₂-XII, cPLA₂-IVa, and iPLA₂-VI. Results reported in relative copy number normalized to GAPDH as average \pm SE; non-asthmatics (n=5), moderate-asthmatics (n=4). * P <0.05.

DISCUSSION

The central new finding is that inherent levels of LPC16:0 and LPC18:0, but not LPC18:1, were significantly elevated in lung lining fluids of subjects with lung function impairment characteristic of moderate asthma. These corresponded to 1.3- and 2-fold respective increases in LPC16:0 and LPC18:0 over non-asthmatic controls. Interestingly, in atopic asthmatic subjects challenged with antigen, LPC16:0 is increased in BALF when compared to saline challenge;¹⁴ however, the LPC level in non-asthmatic control was not reported to ascertain the effects in the absence of antigen challenge in asthmatics. Reports indicate that among acyl-lysophospholipid species, LPC16:0 and LPC18:0 exert the greatest pro-inflammatory activities, such as eosinophil adhesion,²⁷ neutrophil priming,²⁸ and cytokine secretion.^{9,10} Altogether, the results implicate a pathogenic role of LPC in the chronic inflammatory injury of the asthmatic airway.

We can only speculate on the inflammatory potential of an elevated LPC content in lung lining fluids of moderate-asthmatics, since precise *in vivo* LPC concentrations are unknown and its bioactivity is dependent on the free form (not bound to albumin or other proteins).¹ In *in vitro* culture studies, LPC concentrations of 1-100 μM are effective in inducing a wide range of inflammatory activities, such as cell proliferation,⁶ migration,^{7,8} increases in endothelial permeability,²⁹ leukocyte adhesion,^{27,30} neutrophil priming,²⁸ and cytokine secretion.^{9,10} The calculation of molar units of LPC from our data indicated 70 μM of LPC16:0 and 140 μM of LPC18:0 from moderate asthmatics, which are values comparable to those used in *in vitro* studies. This finding suggests that the increased LPC content in lungs of moderate-asthmatics could be sufficient in promotion of airway inflammatory injury.

The results indicate that the increased LPC content in lungs of moderate-asthmatics was accompanied by significant increases in the PLA₂ activity in the lung lining fluids, providing evidence that increased generation of LPC was likely attributed to secreted PLA₂. Moreover, the PLA₂-induced increase in LPC is expected to be accompanied by concomitant equimolar amounts of free fatty acids, which can be arachidonic acid depending on the substrate phosphatidylcholine species. The well-recognized pathway of arachidonic acid metabolism by cyclooxygenases and lipoxygenases will, in turn, produce respective prostaglandins and leukotrienes, which are believed to be important lipid mediators in asthma. Thus, increases in LPC together with increases in arachidonic acid metabolites suggests that the inflammatory potential of PLA₂ is likely significantly greater than recognized previously.

Furthermore, the increased PLA₂ activity was attributed to, at least in part, to upregulated sPLA₂-X mRNA in the leukocytic infiltrate, a finding consistent with the report of overexpression of sPLA₂-X in airway epithelial cells and bronchial macrophages of human asthmatic subjects.²⁰ Although our protocol did not

allow us to identify the cell type(s) responsible for the upregulated sPLA₂-X, analysis of the cell differential indicated that in moderate-asthmatics, the infiltrate population shifted towards increasing eosinophils, neutrophils, and lymphocytes (Table 1).

In summary, the lung lining fluids in moderate-asthmatics showed an inherently elevated content of LPC16:0 and LPC18:0. Such increased LPC is a potential injurious mediator in the initiation and/or progression of airway inflammatory injury in asthma.

ACKNOWLEDGMENTS

This work was supported by a grant from the Rush Translational Scientific Consortium, Rush University Medical Center, Chicago, IL, USA.

REFERENCES

- Schmitz G, Ruebsaamen K. Metabolism and atherogenic disease association of lysophosphatidylcholine. *Atherosclerosis* 2010;208:10-8.
- Matsumoto T, Kobayashi T, Kamata K. Role of lysophosphatidylcholine (LPC) in atherosclerosis. *Curr Med Chem* 2007;14:3209-20.
- Ha CY, Kim JY, Paik JK, Kim OY, Paik YH, Lee EJ, Lee JH. The association of specific metabolites of lipid metabolism with markers of oxidative stress, inflammation and arterial stiffness in men with newly diagnosed type 2 diabetes. *Clin Endocrinol (Oxf)* 2012;76:674-82.
- Sasagawa T, Okita M, Murakami J, Kato T, Watanabe A. Abnormal serum lysophospholipids in multiple myeloma patients. *Lipids* 1999;34:17-21.
- Mehta D, Gupta S, Gaur SN, Gangal SV, Agrawal KP. Increased leukocyte phospholipase A2 activity and plasma lysophosphatidylcholine levels in asthma and rhinitis and their relationship to airway sensitivity to histamine. *Am Rev Respir Dis* 1990;142:157-61.
- Schaefer CA, Kuhlmann CR, Gast C, Weiterer S, Li F, Most AK, Neumann T, Backenköhler U, Tillmanns H, Waldecker B, Wiecha J, Erdogan A. Statins prevent oxidized low-density lipoprotein- and lysophosphatidylcholine-induced proliferation of human endothelial cells. *Vascul Pharmacol* 2004;41:67-73.
- Radu CG, Yang LV, Riedinger M, Au M, Witte ON. T cell chemotaxis to lysophosphatidylcholine through the G2A receptor. *Proc Natl Acad Sci U S A* 2004;101:245-50.
- Kohno M, Yokokawa K, Yasunari K, Minami M, Kano H, Hanehira T, Yoshikawa J. Induction by lysophosphatidylcholine, a major phospholipid component of atherogenic lipoproteins, of human coronary artery smooth muscle cell migration. *Circulation* 1998;98:353-9.
- Liu-Wu Y, Hurt-Camejo E, Wiklund O. Lysophosphatidylcholine induces the production of IL-1 β by human monocytes. *Atherosclerosis* 1998;137:351-7.
- Spangelo BL, Jarvis WD. Lysophosphatidylcholine stimulates interleukin-6 release from rat anterior pituitary cells in vitro. *Endocrinology* 1996;137:4419-26.
- Takeshita S, Inoue N, Gao D, Rikitake Y, Kawashima S, Tawa R, Sakurai H, Yokoyama M. Lysophosphatidylcholine enhances superoxide anions production via endothelial NADH/NADPH oxidase. *J Atheroscler Thromb* 2000;7:238-46.

12. Zou Y, Kim CH, Chung JH, Kim JY, Chung SW, Kim MK, Im DS, Lee J, Yu BP, Chung HY. Upregulation of endothelial adhesion molecules by lysophosphatidylcholine. Involvement of G protein-coupled receptor GPR4. *FEBS J* 2007;274:2573-84.
13. Nakos G, Kitsiouli EI, Tsangaris I, Lekka ME. Bronchoalveolar lavage fluid characteristics of early intermediate and late phases of ARDS. Alterations in leukocytes, proteins, PAF and surfactant components. *Intensive Care Med* 1998;24:296-303.
14. Chilton FH, Averill FJ, Hubbard WC, Fonteh AN, Triggiani M, Liu MC. Antigen-induced generation of lyso-phospholipids in human airways. *J Exp Med* 1996;183:2235-45.
15. Arbibe L, Koumanov K, Vial D, Rougeot C, Faure G, Havet N, Longacre S, Vargaftig BB, Béréziat G, Voelker DR, Wolf C, Touqui L. Generation of lyso-phospholipids from surfactant in acute lung injury is mediated by type-II phospholipase A2 and inhibited by a direct surfactant protein A-phospholipase A2 protein interaction. *J Clin Invest* 1998;102:1152-60.
16. Nishiyama O, Kume H, Kondo M, Ito Y, Ito M, Yamaki K. Role of lysophosphatidylcholine in eosinophil infiltration and resistance in airways. *Clin Exp Pharmacol Physiol* 2004;31:179-84.
17. Nobata K, Kurashima K, Fujimura M, Abo M, Ishiura Y, Kasahara K, Nakao S. Inhaled lysophosphatidylcholine provokes bronchoconstriction in guinea pigs in vivo. *Eur J Pharmacol* 2005;520:150-5.
18. Niewoehner DE, Rice K, Sinha AA, Wangenstein D. Injurious effects of lysophosphatidylcholine on barrier properties of alveolar epithelium. *J Appl Physiol* 1987;63:1979-86.
19. Lindahl M, Hede AR, Tagesson C. Lysophosphatidylcholine increases airway and capillary permeability in the isolated perfused rat lung. *Exp Lung Res* 1986;11:1-12.
20. Hallstrand TS, Chi EY, Singer AG, Gelb MH, Henderson WR Jr. Secreted phospholipase A2 group X overexpression in asthma and bronchial hyperresponsiveness. *Am J Respir Crit Care Med* 2007;176:1072-8.
21. Bowton DL, Seeds MC, Fasano MB, Goldsmith B, Bass DA. Phospholipase A2 and arachidonate increase in bronchoalveolar lavage fluid after inhaled antigen challenge in asthmatics. *Am J Respir Crit Care Med* 1997;155:421-5.
22. Triggiani M, Giannattasio G, Calabrese C, Loffredo S, Granata F, Fiorello A, Santini M, Gelb MH, Marone G. Lung mast cells are a source of secreted phospholipases A2. *J Allergy Clin Immunol* 2009;124:558-65, 565.e1-3.
23. Sane AC, Mendenhall T, Bass DA. Secretory phospholipase A2 activity is elevated in bronchoalveolar lavage fluid after ovalbumin sensitization of guinea pigs. *J Leukoc Biol* 1996;60:704-9.
24. Chung YW, Oh HY, Kim JY, Kim JH, Kim IY. Allergen-induced proteolytic cleavage of annexin-1 and activation of cytosolic phospholipase A2 in the lungs of a mouse model of asthma. *Proteomics* 2004;4:3328-34.
25. Burke JE, Dennis EA. Phospholipase A2 structure/function, mechanism, and signaling. *J Lipid Res* 2009;50 Suppl:S237-42.
26. Global Initiative for Asthma (GINA). GINA report. United States: Global Initiative for Asthma; 2007. Available from: <http://www.gin-asthma.org>.
27. Zhu X, Learoyd J, Butt S, Zhu L, Usatyuk PV, Natarajan V, Munoz NM, Leff AR. Regulation of eosinophil adhesion by lysophosphatidylcholine via a non-store-operated Ca²⁺ channel. *Am J Respir Cell Mol Biol* 2007;36:585-93.
28. Silliman CC, Elzi DJ, Ambruso DR, Musters RJ, Hamiel C, Harbeck RJ, Paterson AJ, Bjornsen AJ, Wyman TH, Kelher M, England KM, McLaughlin-Malaxecheberria N, Barnett CC, Aiboshi J, Bannerjee A. Lysophosphatidylcholines prime the NADPH oxidase and stimulate multiple neutrophil functions through changes in cytosolic calcium. *J Leukoc Biol* 2003;73:511-24.
29. Huang F, Subbaiah PV, Holian O, Zhang J, Johnson A, Gertzberg N, Lum H. Lysophosphatidylcholine increases endothelial permeability: role of PKC α and RhoA cross talk. *Am J Physiol Lung Cell Mol Physiol* 2005;289:L176-85.
30. Huang F, Mehta D, Predescu S, Kim KS, Lum H. A novel lysophospholipid- and pH-sensitive receptor, GPR4, in brain endothelial cells regulates monocyte transmigration. *Endothelium* 2007;14:25-34.